ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

An exploratory phase II trial of immune checkpoint inhibitors (ICIs, anti-PD-1/anti-PD-L1) as second-line treatment with advanced non-small cell lung cancer (NSCLC) who had long-term response to first-line immunotherapy (with or without chemotherapy). This study aims to evaluate efficacy and safety of ICI rechallenge in long-term responders to prior ICI. Furthermore, it seeks to identify biomarkers capable of predicting the efficacy of immunotherapy and prognosis.

Trial Details

NCT ID
NCT06388031
Phase
PHASE2
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Immune checkpoint inhibitor
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Participants must have a thorough understanding of this study and voluntarily sign an informed consent form (ICF);
  • Age between 18 and 80 years, any gender;
  • Histologically or cytologically confirmed stage III-IV non-small cell lung cancer (NSCLC);
  • Previous treated with first-line immunotherapy (immunotherapeutic agents include currently marketed anti-PD-L1 or anti-PD-1 monoclonal antibodies: …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →